OSI Gains US Marketing Rights for Gelclair™ from Celgene

By Business Review Editor

Pharma Deals Review: Vol 2003 Issue 38 (Table of Contents)

Published: 3 Jul-2003

DOI: 10.3833/pdr.v2003.i38.889     ISSN: 1756-7874

Section: Distribution & Marketing

Abstract

OSI Pharmaceuticals has recovered US marketing rights to Gelclair™ for oncology indications from Celgene...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details